Cardiometabolic Disease and Substrate Metabolism

ConditionsPreeclampsia Gestational Diabetes Mellitus (GDM)Preeclampsia (PE)Preeclampsia (PE) Risk Gestational Diabetes Gestational Diabetes Mellitus in Pregnancy Cardiometabolic Diseases Insulin Resistance Placental Dysfunction Pregnancy Pregnancy Complications Gestational Complications

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18-45

SponsorUniversity of Tennessee Graduate School of Medicine

About this trial

This study's primary purpose is to determine the potential relationship between cardiometabolic disease, specifically insulin resistance (HOMA-IR), and maternal lipid oxidation.

Eligibility criteria

Qualifiers

Age 18-45

Any pre-pregnancy BMI

At least one high risk OR one moderate risk factor for pre-eclampsia based on ACOG and USPSTF guidelines

Willingness to adhere to aspirin therapy

Disqualifiers

Type 2 Diabetes Mellitus

Type 1 Diabetes Mellitus

Current gestational diabetes mellitus

Current/active platelet disorder or bleeding diathesis (thrombocytopenia of any etiology, idiopathic thrombocytopenic purpura/ITP, thrombotic thrombocytopenic purpura/TTP, von Willebrand disease, etc.)

Trial design

Treatments tested in this trial

Not listed

Trial groups

50 Participants

are grouped into 1 trial group

Locations

University of Tennessee Graduate School of Medicine37920, KnoxvilleTennessee, United States

Sponsors and collaborators

University of Tennessee Graduate School of Medicine

Lead sponsor

Source ClinicalTrials.gov